Muscle age and lifespan: beyond physiological strength-NHRI has discovered a direct link between skeletal muscle aging and mortality through thermogenic and metabolic abnormalities

Using genetic modified mouse models, research at t…

Continue reading

Share Button

NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp

The National Health Research Institutes (NHRI) and…

Continue reading

Share Button

Congratulation to Dr. Lun Kelvin Tsou, Associate Investigator of IBPR, on receiving the 14th Tien Te Lee Biomedical Young Scientists Award

Dr. Lun Kelvin Tsou, Associate Investigator of IBP…

Continue reading

Share Button

Congratulation to Dr. Hsing-Pang Hsieh, Investigator of IBPR, on receiving 2017 MOST Outstanding Research Award

Dr. Hsing-Pang Hsieh, Investigator of IBPR, was aw…

Continue reading

Share Button

Congratulation to Dr. Lun Kelvin Tsou, Associate Investigator of IBPR, on receiving 2018 NHRI Research Achievement Award

Dr. Lun Kelvin Tsou, Associate Investigator of IBP…

Continue reading

Share Button

National Health Research Institutes Announces FDA approval of Investigational New Drug (IND) Applications for Two Novel Small Molecules, DBPR211 and DBPR114

Institute of Biotechnology and Pharmaceutical Rese…

Continue reading

Share Button

Congratulations to the team that leads the project: “Pre-clinical investigation of the anti-cancer multi-kinase inhibitor:DBPR114”from IBPR for receiving the 26th Wang Ming-Ning Award by the Wang Ming-Ning memorial foundation.

Leading by Dr. Hsing-Pang Hsieh, the DBPR114 team …

Continue reading

Share Button

Congratulations to the team that leads the project: ‘’Developing of Novel Anti-cancer Drug Delivery System’’ from IBPR for receiving the 2016 Technology Achievement Award by the Ministry of Economic Affairs (MOEA).

To strengthen the integration of technical researc…

Continue reading

Share Button

Congratulations to the team that leads the project: ‘’The discovery and development of a novel small-molecule Hepatitis C virus inhibitor, DBPR110’’ from IBPR for receiving the 2016 Technology Transfer Award – Silver Medal Award by Taipei City Government.

The “Technology Transfer Award” is one…

Continue reading

Share Button

DBPR211, a novel small-molecule anti-type 2 diabetes drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)

Institute of Biotechnology and Pharmaceutical Rese…

Continue reading

Share Button